Log in Start free →
—
—
Health Care · NYSE NYSE · LLY

Eli Lilly & Co

$1,443.50 +$18.19 +1.26% CLOSE 11.13.26 AFTER HOURS $1,439.59
Convergence score
- / 5.0 —
+0.0 vs last report
Overall valuation
Overvalued
Aggregated across multiple horizons
Consensus target (12mo)
$1,463.40 +1.4%
Range $940.00 — $1,700.00
Sector
Health Care
NYSE · Tracked daily
Today's snapshot

Where the signals stand.

REPORT 11.13.26
UV Convergence Score
REPORT 11.13.26
-
/ 5.0
—
Consensus signal A
5.0
Consensus signal D
5.0
Analyst average
4.4
Multi-signal aggregate How CSR works →
Day Range
$1,419.81 – $1,449.64
52W Range
$850.51 – $1,460.00
Volume
1.9M
Avg Vol
2.6M
Mkt Cap
$1.29T
P/E
46.85
EPS (TTM)
$30.81
Div Yield
0.48%
Beta
0.39
Today's convergence

Convergence score sits at - with overall valuation reading as overvalued. Drivers across the horizons inform the aggregate. Open the deep dives for valuation, analyst, or financial detail.

Valuation
Overvalued
CSR direction
—
Last close
$1,443.50
Sector
Health Care
Valuation
Three horizons
UPDATED 11.13.26
Short term
0–3 MO
No target —
Medium term
3–12 MO
No target —
Long term
12–36 MO
$466.57-67.7% Overvalued
Open valuation →
Analysts
Coverage & consensus
4 PANELS
Mean target (12mo)
$1,463.40 +1.4%
RANGE $940.00 — $1,700.00
Analyst consensus
Consensus rating Buy
Blended score 4.1 / 5
Analysts tracked 124
Open analysts →
Financials
Key metrics
LATEST
P/E
46.85
EPS (TTM)
$30.81
Mkt Cap
$1.29T
Div Yield
0.48%
Beta
0.39
52W Range
$850.51 – $1,460.00
Open financials →
Reports
Login for history

Sign in to view the historical report archive for this stock.

Log in →
Valuation breakdown

Three horizons, one consensus.

UPDATED 11.13.26
Short term
0–3 MO
—
Consensus target
No target available
Medium term
3–12 MO
—
Consensus target
No target available
Long term
12–36 MO
Overvalued
Consensus target
$466.57 -67.7%

UVStocks in-house sector-relative valuation model.

Signal breakdown

What’s driving the score.

EACH SIGNAL RATED 1.0 — 5.0
Top-level breakdown
Valuation: PE Ratio: 46.85PEG Ratio: -DE Ratio: -
Free Cash Flow: $9.34BPB Ratio: -PS Ratio: -Dividend: $1.73
Analyst coverage

Blended analyst consensus & targets.

4 PANELS · UPDATED 11.13.26
Analyst consensus RATING · SCORE · PANELS · ANALYSTS
Rating Blended score Panels Analysts
Buy 4.1 4 124
Price targets LOW · MEAN · MEDIAN · HIGH · UPSIDE
Coverage Low Mean Median High Upside
All panels $940.00 $1,463.40 $1,570.00 $1,700.00 +1.4%
Rating distribution STRONG BUY · BUY · HOLD · SELL · STRONG SELL
Coverage SB B H S SS
All panels 5 20 4 1 1
Rating trend CURRENT VS 1M / 2M / 3M
Period Rating Avg Analysts
Current — — —
1 Mo Ago — — —
2 Mo Ago — — —
3 Mo Ago — — —
Most recent analyst action LATEST DESK ACTION
Date
—
Firm
—
Action
—
Rating
—
Target
—
Related links
Financials

Full financial snapshot.

UPDATED 11.13.26
Quote snapshot 15 FIELDS
Prev Close
$1,425.55
Open
$1,429.91
Day Low
$1,419.81
Day High
$1,449.64
Bid
$1,438.60
Ask
$1,441.00
52W Low
$850.51
52W High
$1,460.00
50D Avg
$1,235.40
200D Avg
$1,107.23
Volume
1.9M
Avg Vol
2.6M
10D Avg Vol
3.5M
52W Change
39.21%
S&P 52W Change
12.75%
Valuation ratios 10 FIELDS
P/E (TTM)
46.85
P/E (Fwd)
28.50
PEG (Fwd)
1.32
P/S
14.87
P/B
31.95
Book Value
$45.19
EV/Revenue
15.39
EV/EBITDA
28.62
Mkt Cap
1.29T
Enterprise Val
1.33T
Profitability & returns 6 FIELDS
Profit Margin
31.90%
Gross Margin
83.63%
Operating Margin
51.25%
EBITDA Margin
53.77%
Return on Assets
21.06%
Return on Equity
86.02%
Growth 3 FIELDS
Revenue Growth (YoY)
38.60%
Earnings Growth (YoY)
16.30%
Earnings Growth (Q)
15.50%
Balance sheet & cash flow 11 FIELDS
Total Revenue
86.46B
EBITDA
46.49B
Total Cash
4.89B
Total Debt
49.5B
Cash / Share
$5.48
Revenue / Share
$96.75
Free Cash Flow
9.34B
Operating CF
30.65B
Debt / Equity
122.92
Current Ratio
1.39
Quick Ratio
0.64
Dividend 5 FIELDS
Fwd Dividend
6.92 (0.48%)
Dividend Yield
0.48%
Payout Ratio
21.71%
5Y Avg Yield
0.75%
Ex-Div Date
2026-11-13
Share statistics 7 FIELDS
Shares Out
890.75M
Float
888.43M
Shares Short
7.21M
% Short of Float
0.81%
Short Ratio
2.84
% Held Insiders
0.16%
% Held Institutions
85.62%
Calendar & events 5 FIELDS
Next Earnings
2026-10-29
Fiscal Year End
2025-12-31
Most Recent Qtr
2026-09-30
Last Split
2:1
Split Date
1997-10-16
Company 2 FIELDS
Industry
Drug Manufacturers - General
Employees
50,000